Cardiol Therapeutics Achieves Key 50% Patient Enrollment Milestone in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis

Core Insights - Cardiol Therapeutics Inc. has surpassed 50% patient enrollment in its Phase III MAVERIC trial, which evaluates CardiolRx™ for preventing disease recurrence in patients with recurrent pericarditis [1][2][3] Company Overview - Cardiol Therapeutics is a late-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for heart disease, with its lead drug candidate being CardiolRx™ [5][9] - The company aims to address the high unmet medical need in recurrent pericarditis, a condition that significantly impacts patients' quality of life [7] Clinical Trial Progress - The MAVERIC trial is designed to enroll approximately 110 patients across 25 leading cardiovascular research centers in the U.S., Canada, and Europe, with full enrollment expected by Q2 2026 [4][6] - The primary endpoint of the trial is freedom from new episodes of recurrent pericarditis after six months of treatment, with secondary endpoints including pain scores and inflammatory biomarker changes [4] Scientific Rationale and Market Potential - Data from the Phase II MAvERIC-Pilot study showed that CardiolRx™ led to rapid and sustained reductions in pericarditis pain and inflammation, supporting its advancement to Phase III [3][4] - The company believes that CardiolRx™'s oral, non-immunosuppressive profile positions it as a more accessible treatment option compared to biologic therapies, which are projected to generate over $800 million in U.S. revenues in 2026 [3][4]